Chugai Pharmaceutical Company

Chugai Pharmaceutical is developing, together with Zhejiang Hisun Pharmaceutical, a Humanized monoclonal antibody targeting interleukin-6.

Peking University First Hospital on March 16 registered an up-to-150 patient study assessing tocilizumab, marketed in China by Roche subsidiary Chugai Pharmaceutical, in combination with the Zhejiang Hisun Pharmaceutical-marketed drug favipiravir in adults with COVID-19 (ChiCTR2000030894). A 94-patient trial assessing Tocilizumab alone has been registered by The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) (ChiCTR2000029765).
Technology: COVID
Industry: Treatments
Headquarters: Japan
Founded Date: N/A
Employees Number: N/A
Funding Status: N/A

Visit Website
Register and Claim Ownership